《Table 1 Predictive factors for complete pathological response in univariate logistic regression ana

  提示：宽带有限、当前游客访问压缩模式

本系列图表出处文件名：随高清版一同展现

《Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer》

1. 获取 高清版本忘记账户？点击这里登录

1. 下载图表忘记账户？点击这里登录

Platelet，apolipoprotein A-1，apolipoprotein B，and the interval were calculated as metrological data，and others are counting data.pCR:Complete pathological response；NLR:Neutrophil-lymphocyte ratio；DTAV:Distance of tumor from the anal verge；TL:Tumor lengt

pCR patients and non-pCR patients did not differ significantly in terms of gender，BMI，CEA，NLR，HB，PLT，ApoA1，ApoB，cT，cN，or TCE in the univariate analysis（P>0.05）；however，significant differences were found for age，tumor differentiation，TL，DTAV，MRF status，interval，and NT regimen（Table 1）.Statistically significant factors in the univariate logistic regression analysis（P≤0.05）to predict pCR were entered into a multivariate analysis，in which NT regimen types（a P<0.05），tumor differentiation（b P<0.05），TL（c P<0.05），and MRF status（d P<0.05）were significantly associated with pCR probability（Table 2）.For the NT regimens，the odds ratio（OR）was 5.339[95%confidence interval（CI）:2.394-11.903]for the mFOLFOX6-RT regimen compared with the capecitabine/deGramont-RT regimen.The mFOLFOX6 regimen and capecitabine/deGramont-RT regimen did not differ significantly.For tumor differentiation，the OR was 2.966（95%CI:1.449-6.069）for well tumor differentiation compared with moderate-poor differentiation.For TL（>3 cm）compared with TL（≤3cm），the OR was 2.608（95%CI:1.347-5.052），and for MRF（-）compared with MRF（+），the OR was 2.729（95%CI:1.199-6.211）.